Welcome to our dedicated page for Nakamoto SEC filings (Ticker: NAKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kindly MD, Inc. (NAKA) SEC filings page provides access to the company’s official regulatory disclosures as a publicly traded issuer. KindlyMD, a patient-first and healthcare data company with integrated healthcare services and a Bitcoin treasury strategy via its subsidiary Nakamoto Holdings Inc., uses filings with the U.S. Securities and Exchange Commission to report material events, corporate actions, and financial information.
Among the key documents available are Current Reports on Form 8-K, which the company uses to disclose significant developments. Recent 8-K filings have addressed topics such as the completion of the merger with Nakamoto, entry into and termination of material loan agreements secured by Bitcoin or other digital assets, authorization of a share repurchase program, receipt of a Nasdaq minimum bid price notice, and the establishment of dates and record dates for annual shareholder meetings. These filings also cover matters like redemption of a secured convertible debenture and the company’s financing arrangements with lenders focused on digital assets.
Investors can also review proxy materials, including the Definitive Proxy Statement on Schedule 14A, which outlines proposals submitted to stockholders, such as the election of directors, approval of converting Kindly MD from a Utah corporation to a Delaware corporation, ratification of the independent registered public accounting firm, and potential adjournment of the annual meeting. Notifications of late filing on Form 12b-25 (NT 10-Q) provide context when additional time is needed to complete quarterly reports, including explanations related to the accounting complexity of the merger with Nakamoto.
On Stock Titan, these filings are complemented by AI-powered tools that help summarize lengthy documents and highlight key points, such as new financing obligations, changes in capital structure, or updates on the company’s Bitcoin treasury strategy. Users can quickly locate information about quarterly and annual reporting, material agreements, shareholder votes, and listing status, as well as track how KindlyMD’s integrated healthcare operations and Bitcoin-focused activities are reflected in its regulatory record.
Amanda Fabiano, Chief Operating Officer of Kindly MD, Inc. (NAKA), reported two grants of restricted stock units on 09/22/2025 that increase her direct beneficial ownership to 4,135,337 shares. One grant covers 751,879 RSUs and the second covers 3,383,458 RSUs; both show a transaction price of $0 and are time-vesting over three years with a 12-month cliff beginning August 15, 2025. After the cliff, 25% vests immediately and the remaining 75% vests in equal quarterly installments over the following 24 months, subject to continued service. The larger grant is further contingent on a performance condition: no shares will vest under that grant unless Fabiano causes Second Gate Advisory, LLC (an entity she owns and controls) to assign or transfer certain business arrangements to the issuer. The Form 4 was signed by an attorney-in-fact on 09/24/2025.
Kindly MD, Inc. (NAKA) reports a grant of 751,879 restricted stock units (RSUs) to reporting person David F. Bailey in a transaction dated 09/22/2025. The RSUs vest over four years with a 12-month cliff measured from August 15, 2025: 25% vests at the end of the cliff and the remaining 75% vests in equal quarterly installments over the following 36 months, subject to continued service. After this grant the reporting person beneficially owns 11,912,451 shares. The RSUs have no purchase price reported and are time-based equity compensation intended to align executive incentives with shareholder outcomes.
Kindly MD, Inc. (NAKA) insider report: Chief Commercial Officer Andrew Creighton was granted 601,503 restricted stock units (RSUs) that will time-vest over four years. There is a 12-month cliff from August 15, 2025, after which 25% vests at cliff completion and the remaining 75% vests in equal quarterly installments over the following 36 months, contingent on continued service. After the grant, Mr. Creighton beneficially owns 3,726,474 shares of common stock. The RSUs were granted at no cash price to the reporting person and are subject to the issuer’s standard vesting and service conditions.
Tyler Matthew Evans, Chief Investment Officer of Kindly MD, Inc. (NAKA), was granted 601,503 restricted stock units (RSUs) on 09/22/2025 at a reported price of $0, bringing his total beneficial ownership to 3,012,188 shares. The RSUs vest over four years with a 12-month cliff beginning August 15, 2025, after which 25% vest at the cliff and the remaining 75% vest in equal quarterly installments over the following 36 months. Vesting is contingent on the reporting person’s continued service through each vesting date. The Form 4 was signed by an attorney-in-fact on 09/24/2025.
Mark W. Yusko, a director of Kindly MD, Inc. (NAKA), reported an acquisition of 112,781 restricted stock units (RSUs) on 09/22/2025. The filing shows these RSUs were granted at a price of $0 and that the reporting person will beneficially own 2,212,781 shares following the grant. The RSUs vest on August 15, 2026 and are subject to the reporting person ontinuing service on the company oard through that vesting date. The Form 4 was signed and submitted by an attorney-in-fact on behalf of the reporting person.
Perianne Boring McNulty, a director of Kindly MD, Inc. (NAKA), reported acquiring 112,781 restricted stock units on 09/22/2025. The RSUs were granted at a $0 price and are scheduled to vest on August 15, 2026, subject to her continued service on the company's board through the vesting date. After this transaction the reporting person beneficially owns 112,781 shares in a direct ownership form. The Form 4 was signed by an attorney-in-fact on 09/24/2025.
Kindly MD, Inc. (NAKA) director Charles Phillip Blackburn was granted 112,781 restricted stock units (RSUs) on 09/22/2025, recorded on a Form 4 filed 09/24/2025. The RSUs carry a $0 purchase price and are reported as directly beneficially owned following the grant.
The RSUs are subject to time-based vesting and will vest on August 15, 2026 provided Blackburn continues to serve on the company’s board through that Vesting Date. After the reported transaction, Blackburn is shown as beneficial owner of 112,781 shares tied to these RSUs.
Kindly MD, Inc. reported that on September 15, 2025 it sent a redemption notice to the holder of its Secured Convertible Debenture dated August 15, 2025. The company plans to redeem on September 29, 2025 all amounts under the debenture that have not been converted by that date, paying cash equal to 100% of the outstanding principal plus a 1.5% payment premium, with payment to be delivered on September 30, 2025. If the holder does not convert any portion of the debenture, the total cash redemption amount including the 1.5% premium would be $203,000,000, and there will be no accrued or unpaid interest due as of the redemption date.
Kindly MD, Inc. filed an 8-K to share a letter it sent to shareholders on September 15, 2025. In the letter, the company explains that it filed a Form S-3 registration statement on September 12, 2025, which is a document that can allow it to sell securities or register securities for resale in the future. The company notes that it expects its share price volatility to increase for a period of time and reiterates its focus on its long-term vision. The shareholder letter is attached as Exhibit 99.1 and is furnished under a Regulation FD disclosure, meaning it is not treated as filed for liability purposes under Section 18 of the Exchange Act.
Kindly MD, Inc. discloses material risks and shareholder details in this S-3ASR filing. The company warns that costs and potential litigation related to a proposed Merger have been and will be incurred, that trading of its securities may be volatile, and that shareholders may face dilution from warrant exercises and future equity issuances. The filing highlights industry-specific regulatory risk for medical cannabis, competitive and technology threats, reliance on key management, and cybersecurity concerns. Significant beneficial ownership stakes are shown, including a holder with 133,928,571 shares (27.19%) and another with 114,246,002 shares (23.94%), and a large block totaling 53,571,429 shares (13.57%). The registrant describes permitted distribution methods for registered shares and undertakes post-effective filing obligations. The document includes officer and director signatures certifying the filing.